Currently, clinically approved drugs targeting chemokines include anti-CCR4 antibodies (Mogamulizumab) and CXCR4 antagonists (Plerixafor, AMD3100), which are utilized in the treatment of hematological malignancies. The gene discussed is CCR4; the disease is hematologic disorder.